Login
$LCTX
$0.80 +$0.00 (0.0%) After hours

$LCTX SEC Filings

Filed On Filing
12 Nov 2026 10-Q
12 Nov 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +3 more

CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED.

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.

29 Jul 2026 SCHEDULE 13G
02 Jul 2026 Form 4: Bradsher Neal C, Director

Granted 125,000 OPTION TO PURCHASE COMMON SHARES

02 Jul 2026 Form 4: Jayasuriya Anula, Director

Granted 125,000 Stock Option (Right to Buy)

02 Jul 2026 Form 4: Mulroy Michael H., Director

Granted 125,000 Stock Option (Right to Buy)

02 Jul 2026 Form 4: Andrews Deborah J, Director

Granted 125,000 Stock Option (Right to Buy)

02 Jul 2026 Form 4: Russell Angus C., Director

Granted 125,000 Stock Option (Right to Buy)

02 Jul 2026 Form 4: Amin Dipti, Director

Granted 125,000 Stock Option (Right to Buy)

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders; Other Events

The annual meeting of shareholders (the “Annual Meeting”) of Lineage Cell Therapeutics, Inc. (the “Company”), was held on June 10, 2026 and involved the election of directors of the Company and two other matters voted upon by the Company...

12 May 2026 10-Q
12 May 2026 8-K: Results of Operations and Financial Condition

CARLSBAD, CA – May 12, 2026 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its ...

29 Apr 2026 ARS
29 Apr 2026 DEFA14A
29 Apr 2026 Proxy statement: annual meeting on June 10, 2026

CEO pay $2.1M, down 17% · say-on-pay vote

23 Mar 2026 EFFECT
19 Mar 2026 CORRESP
16 Mar 2026 UPLOAD

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support